Augmented Rififylin Is a Risk Factor Linked to Aberrant Cardiomyocyte Function, Short-QT Interval and Hypertension

Title
Augmented Rififylin Is a Risk Factor Linked to Aberrant Cardiomyocyte Function, Short-QT Interval and Hypertension
Authors
Keywords
-
Journal
HYPERTENSION
Volume 57, Issue 4, Pages 764-771
Publisher
Ovid Technologies (Wolters Kluwer Health)
Online
2011-03-02
DOI
10.1161/hypertensionaha.110.165803

Ask authors/readers for more resources

Find Funding. Review Successful Grants.

Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.

Explore

Add your recorded webinar

Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.

Upload Now